FGF-23

FGF-23 Informations sur la molécule

Nom anglais	Fibroblast growth factor 23	Nombre de médicaments commercialisés	1
Nombre de médicaments cliniques	1	Alias de la cible	HFTC2，Tumor-Derived Hypophosphatemia Inducing Factor，UNQ3027/PRO9828，Tumor-derived hypophosphatemia-inducing factor，HYPF，FGF23，Fibroblast Growth Factor 23，Phosphatonin，FGF-23，HPDR2，PHPTC，ADHR，FGFN
Phase de R&D la plus avancée	Approved

Nom anglais	Fibroblast growth factor 23
Alias de la cible	HFTC2，Tumor-Derived Hypophosphatemia Inducing Factor，UNQ3027/PRO9828，Tumor-derived hypophosphatemia-inducing factor，HYPF，FGF23，Fibroblast Growth Factor 23，Phosphatonin，FGF-23，HPDR2，PHPTC，ADHR，FGFN
Nombre de médicaments commercialisés	1
Nombre de médicaments cliniques	1
Phase de R&D la plus avancée	Approved

FGF-23 Liste de produits

Attribut
Protein (1)
Bibliothèque de produits
En ligne (1)
Espèces
Human (1)
Étiquette
His Tag (1)
Marqueur
Unconjugated (1)

Numéro de produit	Espèces	Système d'expression	Description du produit	Structure protéique	Pureté	Caractéristiques	Pré-commande/Commande
FG3-H52H3	Human	HEK293	Human FGF-23 (R179Q) Protein, His Tag, low endotoxin				Ajouter au panier

Quantité totale1

FGF-23Contexte de la molécule

Fibroblast growth factor 23 (FGF23) is is an endocrine member of the family of FGFs and mainly produced in the bone and, upon secretion, forms a complex with a FGF receptor and coreceptor αKlotho. FGF23 can exert several endocrine functions, such as acting as a hormone on the kidney, stimulating phosphate excretion and suppressing formation of 1,25(OH)2D3, active vitamin D. Moreover, it has paracrine activities on several cell types, including neutrophils and hepatocytes. FGF23 and phosphate have been revealed to be factors relevant in cancer. FGF23 is particularly significant for those forms of cancer primarily affecting bone (e.g., multiple myeloma) or characterized by bone metastasis.

FGF-23Alias de la molécule

FGF23,HYPF,FGF-23,ADHR,HPDR2

Informations sur les médicaments cliniques

Nom anglais	Code de recherche	Phase de R&D	Entreprise	Indication	Essai clinique
KK-8123	KK8123; KK-8123	Phase 2 Clinical	Kyowa Kirin Inc	Familial Hypophosphatemic Rickets	Details

Informations sur les médicaments commercialisés

Nom anglais	Code de recherche	Phase de R&D	Entreprise	Plus ancien nom de marque	Pays d'approbation le plus ancien	Indication la plus ancienne	Société d'approbation la plus ancienne	Date d'approbation la plus ancienne	Indication	Essai clinique
Burosumab	KRN-23; UX-023	Approved	Kyowa Hakko Kirin Co Ltd	Crysvita, 麟平	EU	Hypophosphatemia, Familial	Kyowa Kirin Holdings Bv	2018-02-19	Familial Hypophosphatemic Rickets; Fibrous Dysplasia of Bone; Genetic Diseases, X-Linked; Hypophosphatemia; Hypophosphatemia, Familial; Nevus, Sebaceous of Jadassohn; Osteomalacia	Details